What now? Alzheimer’s drugmakers ponder the path to approval

Listen to the article 7 min This audio is auto-generated. Please let us know if you have feedback. Last week, Medicare rendered a fateful decision that’s become the latest flashpoint in Biogen’s ongoing saga with Aduhelm. As part of a new finalized policy, the Centers for Medicare and Medicaid Services (CMS) will limit coverage for … Read more